High Cholesterol

Clinical Trial Finder

Many patients with high cholesterol are interested in participating in the latest research regarding their condition. This Clinical Trial Finder can help you—or a loved one—easily find ongoing cardiovascular clinical research trials for which you might qualify. This list is a service of the U.S. National Institutes of Health called clinicaltrials.gov, a database of publicly and privately supported clinical studies.

Simply click on the trial below that interests you to learn how you might participate.

Detection of Familial Hypercholesterolaemia in Cardiovascular Disease Registry

Conditions:   Familial Hypercholesterolemia;   Cardiac Event;   Percutaneous Coronary Intervention
Intervention:  
Sponsors:   University College, London;   Aegerion Pharmaceuticals, Inc.
Completed - verified July 2015

A Clinical Trial to Assess the Long Term Safety and Tolerability of MK-0653H in Japanese Participants With Hypercholesterolemia (MK-0653H-833)

Conditions:   Hypercholesterolemia;   Familial Hypercholesterolemia
Interventions:   Drug: Ezetimibe;   Drug: Rosuvastatin
Sponsor:   Merck Sharp & Dohme Corp.
Recruiting - verified May 2016

Effectiveness of Treatment of Hypercholesterolemia With Rosuvastatin and Ezetimibe

Condition:   Hypercholesterolemia
Intervention:   Drug: Rosuvastatin and Ezetimibe morning or evening administration
Sponsor:   Collegium Medicum w Bydgoszczy
Recruiting - verified May 2016

Trial of Antroquinonol in Patients With Hypercholesterolemia and Hyperlipidemia

Condition:   Hyperlipidemias
Interventions:   Drug: Antroquinonol;   Drug: placebo
Sponsor:   Golden Biotechnology Corporation
Recruiting - verified March 2016

A Gene Therapy Study for Homozygous Familial Hypercholesterolemia (HoFH)

Condition:   Homozygous Familial Hypercholesterolemia
Intervention:   Genetic: AAV directed hLDLR gene therapy
Sponsor:   University of Pennsylvania
Recruiting - verified May 2016

Text Messaging to Promote Walking Among Latino Adults at Risk for Peripheral Arterial Disease

Condition:   Peripheral Arterial Disease
Interventions:   Other: Text Messages;   Other: Phone Calls;   Other: Handout
Sponsors:   University of Kansas Medical Center;   National Institute on Aging (NIA)
Recruiting - verified May 2016

The Cholesterol Lowering Effects of Strawberry

Conditions:   Hypercholesterolemia;   Glycemic Response
Interventions:   Dietary Supplement: Active Treatment Beverage;   Dietary Supplement: Placebo Treatment Beverage
Sponsor:   Institute for Food Safety and Health, United States
Recruiting - verified May 2016

Efficacy and Safety of Alirocumab Versus Placebo on Top of Maximally Tolerated Lipid Lowering Therapy in Patients With Hypercholesterolemia Who Have Type 1 or Type 2 Diabetes and Are Treated With Insulin (ODYSSEY DM - Insulin)

Condition:   Hypercholesterolaemia
Interventions:   Drug: ALIROCUMAB SAR236553 (REGN727);   Drug: placebo;   Drug: insulin;   Drug: insulin;   Drug: statin;   Drug: lipid modifying therapy
Sponsors:   Sanofi;   Regeneron Pharmaceuticals
Recruiting - verified May 2016

Efficacy and Safety of Alirocumab in Patients With Hypercholesterolemia Not Adequately Controlled With Non-statin Lipid Modifying Therapy or the Lowest Strength of Statin

Condition:   Hypercholesterolaemia
Interventions:   Drug: alirocumab SAR236553 (REGN727);   Drug: placebo;   Drug: atorvastatin;   Drug: fenofibrate;   Drug: bezafibrate;   Drug: ezetimibe
Sponsors:   Sanofi;   Regeneron Pharmaceuticals
Recruiting - verified May 2016

Trial Assessing Evolocumab(AMG145) Compared to LDL-C Apheresis in Subjects Receiving LDL-C Apheresis Prior to Study Enrollment

Condition:   Hypercholesterolemia
Interventions:   Biological: evolocumab (AMG 145);   Other: Low Density Lipoprotein Cholesterol (LDL-C) Apheresis
Sponsor:   Amgen
Recruiting - verified May 2016

Safety, Tolerability, and Effect of Alirocumab in High Cardiovascular Risk Patients With Severe Hypercholesterolemia Not Adequately Controlled With Conventional Lipid-modifying Therapies (ODYSSEY APPRISE)

Condition:   Hypercholesterolemia
Interventions:   Drug: ALIROCUMAB SAR236553 (REGN727);   Drug: placebo (for injection training only)
Sponsors:   Sanofi;   Regeneron Pharmaceuticals
Recruiting - verified May 2016

Atorvastatin Study in Cardiovascular Disease Risk

Conditions:   Hypercholesterolemia;   Dyslipidemia
Intervention:  
Sponsor:   Elpen Pharmaceutical Co. Inc.
Completed - verified May 2016

Trial Assessing Efficacy, Safety and Tolerability of PCSK9 Inhibition in Paediatric Subjects With Genetic LDL Disorders

Condition:   Heterozygous Familial Hypercholesterolemia
Interventions:   Drug: Evolocumab;   Drug: Placebo
Sponsor:   Amgen
Recruiting - verified May 2016

A Study to Identify and Characterize LAL-D Patients in High-risk Populations

Condition:   Lysosomal Acid Lipase Deficiency
Intervention:  
Sponsor:   Alexion Pharmaceuticals
Terminated - verified May 2016

Evaluation of Alirocumab in Addition to Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia in South Korea and Taiwan

Condition:   Hypercholesterolemia
Interventions:   Drug: alirocumab SAR236553/REGN727;   Drug: placebo
Sponsor:   Sanofi
Completed - verified May 2016

Use of Decision Aids in Clinical Encounters

Condition:   Diabetes, Depression, Cardiovascular Disease,Hypercholesterolemia, Osteoporosis
Interventions:   Other: Active Implementation of ShareEBM Toolkit;   Other: Passive Dissemination of Share EBM
Sponsor:   Mayo Clinic
Completed - verified May 2016

A 52 Week Study To Assess The Use Of Bococizumab (PF-04950615; RN316) In Subjects With Heterozygous Familial Hypercholesterolemia

Condition:   Heterozygous Familial Hypercholesterolemia
Interventions:   Drug: Bococizumab (PF-04950615;RN316);   Other: Placebo
Sponsor:   Pfizer
Completed - verified May 2016

Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular Events

Condition:   Hyperlipidemia
Interventions:   Drug: Bococizumab (PF-04950615; RN316);   Other: Placebo
Sponsor:   Pfizer
Recruiting - verified May 2016